| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2015: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2013: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Outline of Final Research Achievements |
The aim of this study is to establish evaluation system of antibody therapy for human malignancies using in vivo imaging system. We established the evaluation system of anti-tumor therapy using human tumor transplantation model into novel hairless highly immunodeficient mice. In primary effusion lymphoma (PEL) and cholangiocarcinoma (CCA) model, we showed that anti-CD47 Antibody (Ab), anti-IL6R Ab and Anti-VEGF Ab effectively suppressed the tumor growth. We also confirmed that human NK cells could form and grow in highly immunodeficient mice. We are now planning to establish the evaluation system of Antibody-dependent cell cytotoxicity (ADCC) using Abs and NK cells. Thus, we successfully established the effective evaluation system for treatment of human malignancies using novel hairless immunodeficient mice and in vivo imaging system.
|
